vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and SR Bancorp, Inc. (SRBK). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $8.4M, roughly 1.1× SR Bancorp, Inc.). SR Bancorp, Inc. runs the higher net margin — 10.0% vs -265.9%, a 275.8% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 6.4%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $3.1M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
SR Bancorp Inc. is a regional bank holding company based in the United States. It offers a full range of consumer and commercial banking services including deposit products, personal loans, mortgage lending, small business financing, and commercial credit solutions, primarily serving local communities and small to mid-sized enterprises in its operating areas.
CLLS vs SRBK — Head-to-Head
Income Statement — Q2 FY2024 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $8.4M |
| Net Profit | $-25.3M | $834.0K |
| Gross Margin | — | — |
| Operating Margin | -181.1% | 13.0% |
| Net Margin | -265.9% | 10.0% |
| Revenue YoY | 375.0% | 6.4% |
| Net Profit YoY | -51.9% | -18.3% |
| EPS (diluted) | $-0.28 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $8.4M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $7.7M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | — | $8.4M | ||
| Q2 24 | $9.5M | $7.9M | ||
| Q1 24 | — | $8.8M |
| Q4 25 | — | $834.0K | ||
| Q3 25 | — | $693.0K | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $537.0K | ||
| Q4 24 | — | $1.0M | ||
| Q3 24 | — | $1.4M | ||
| Q2 24 | $-25.3M | $-3.0M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | — | 20.6% | ||
| Q2 24 | -181.1% | -34.0% | ||
| Q1 24 | — | 15.4% |
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | 8.5% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | 16.3% | ||
| Q2 24 | -265.9% | -38.2% | ||
| Q1 24 | — | 12.1% |
| Q4 25 | — | $0.11 | ||
| Q3 25 | — | $0.09 | ||
| Q2 25 | — | $0.27 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.12 | ||
| Q3 24 | — | $0.16 | ||
| Q2 24 | $-0.28 | $8.14 | ||
| Q1 24 | — | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $188.5M |
| Total Assets | $407.1M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.8M | ||
| Q3 25 | — | $58.3M | ||
| Q2 25 | — | $57.8M | ||
| Q1 25 | — | $62.2M | ||
| Q4 24 | — | $53.4M | ||
| Q3 24 | — | $47.3M | ||
| Q2 24 | $149.0M | $45.9M | ||
| Q1 24 | — | $72.5M |
| Q4 25 | — | $188.5M | ||
| Q3 25 | — | $191.9M | ||
| Q2 25 | — | $193.8M | ||
| Q1 25 | — | $195.1M | ||
| Q4 24 | — | $198.1M | ||
| Q3 24 | — | $200.5M | ||
| Q2 24 | $148.6M | $199.5M | ||
| Q1 24 | — | $199.3M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $407.1M | $1.0B | ||
| Q1 24 | — | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $3.6M |
| Free Cash FlowOCF − Capex | $27.6M | $3.1M |
| FCF MarginFCF / Revenue | 290.5% | 37.0% |
| Capex IntensityCapex / Revenue | 13.2% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.6M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | $28.9M | $-1.7M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | $3.1M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $4.2M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | $27.6M | $-2.8M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | — | 37.0% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | — | 55.9% | ||
| Q1 25 | — | 32.3% | ||
| Q4 24 | — | -19.5% | ||
| Q3 24 | — | 20.3% | ||
| Q2 24 | 290.5% | -35.8% | ||
| Q1 24 | — | -45.2% |
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | 13.2% | 13.9% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 1.76× | ||
| Q2 25 | — | 2.11× | ||
| Q1 25 | — | 4.79× | ||
| Q4 24 | — | -1.40× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -3.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
